Hamilton Thorne Ltd. (HTLZF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HTLZF steht fuer Hamilton Thorne Ltd., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 53/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Hamilton Thorne Ltd. (HTLZF) Gesundheitswesen & Pipeline-Uebersicht
Hamilton Thorne Ltd. provides advanced solutions for assisted reproductive technologies (ART), research, and cell biology, offering precision instruments, consumables, and software to a global network of fertility clinics, hospitals, and research institutions, with a focus on innovation and comprehensive ART solutions.
Investmentthese
Hamilton Thorne Ltd. presents a compelling investment case driven by the growing demand for assisted reproductive technologies and the company's comprehensive product portfolio. The company's focus on innovation and expansion into new markets, particularly in emerging economies, is expected to fuel revenue growth. A key value driver is the increasing adoption of advanced ART techniques, which require Hamilton Thorne's specialized equipment and software. The company's established distribution network and direct sales force in key markets provide a competitive advantage. However, the company's negative profit margin of -0.9% and high P/E ratio of -396.97 warrant careful consideration. Successful execution of growth strategies and improved profitability are crucial for realizing the company's long-term potential.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.25 billion reflects the company's current valuation in the assisted reproductive technology market.
- Gross Margin of 50.4% indicates strong pricing power and efficient cost management in its product offerings.
- The company serves approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries.
- Beta of 0.41 suggests lower volatility compared to the overall market, potentially offering stability in investment portfolios.
- Hamilton Thorne Ltd. operates in the growing ART market, driven by increasing infertility rates and advancements in reproductive technologies.
Wettbewerber & Vergleichsunternehmen
Staerken
- Comprehensive product portfolio for ART and cell biology.
- Global distribution network and direct sales force.
- Strong brand reputation in the ART market.
- Expertise in precision instruments and software solutions.
Schwaechen
- Negative profit margin.
- High P/E ratio.
- Dependence on the ART market.
- Limited presence in some emerging markets.
Katalysatoren
- Ongoing: Increasing global demand for assisted reproductive technologies (ART) due to rising infertility rates.
- Upcoming: Potential regulatory approvals for new ART technologies and procedures.
- Ongoing: Strategic partnerships and acquisitions to expand market reach and product portfolio.
- Upcoming: Launch of new and improved software solutions for ART management.
- Ongoing: Expansion into emerging markets with growing ART adoption rates.
Risiken
- Potential: Competition from established and emerging ART equipment and service providers.
- Potential: Regulatory changes affecting ART procedures and reimbursement rates.
- Potential: Economic downturns impacting healthcare spending and ART adoption.
- Ongoing: Negative profit margin and high P/E ratio.
- Potential: Technological obsolescence and the need for continuous innovation.
Wachstumschancen
- Expansion into Emerging Markets: Hamilton Thorne has the opportunity to expand its presence in emerging markets, where access to ART services is growing. These regions often have less competition and increasing demand for advanced reproductive technologies. By establishing strategic partnerships and distribution networks, Hamilton Thorne can capitalize on the growing ART market in countries with improving healthcare infrastructure. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- Development of New ART Technologies: Investing in research and development to create innovative ART technologies can drive future growth. This includes developing more advanced imaging systems, laser technologies, and software solutions for improving the success rates of ART procedures. By staying at the forefront of technological advancements, Hamilton Thorne can attract new customers and maintain its competitive edge. The timeline for realizing revenue from new technologies is approximately 2-4 years.
- Strategic Acquisitions: Hamilton Thorne can pursue strategic acquisitions of complementary businesses to expand its product portfolio and market reach. Acquiring companies with expertise in specific areas of ART or cell biology can enhance Hamilton Thorne's offerings and create synergies. This strategy can accelerate growth and strengthen the company's position in the market. The timeline for integrating acquisitions and realizing their benefits is typically 1-3 years.
- Increased Focus on Consumables: Consumables represent a recurring revenue stream for Hamilton Thorne. By expanding its range of consumables and increasing sales to existing customers, the company can generate stable and predictable revenue. This includes developing new and improved consumables for ART procedures and offering attractive pricing and service packages. The impact on revenue can be seen within 1-2 years.
- Enhancing Software Solutions: Hamilton Thorne's software solutions play a crucial role in ART procedures. By continuously improving and expanding its software offerings, the company can provide added value to its customers and differentiate itself from competitors. This includes developing user-friendly interfaces, advanced data analytics tools, and seamless integration with other ART equipment. The timeline for developing and implementing new software features is approximately 6-18 months.
Chancen
- Expansion into new geographic markets.
- Development of innovative ART technologies.
- Strategic acquisitions of complementary businesses.
- Increased focus on consumables and recurring revenue streams.
Risiken
- Competition from other ART equipment and service providers.
- Regulatory changes affecting ART procedures.
- Economic downturns impacting healthcare spending.
- Technological obsolescence.
Wettbewerbsvorteile
- Specialized expertise in assisted reproductive technologies (ART).
- Comprehensive product portfolio covering various aspects of ART and cell biology.
- Established distribution network and direct sales force.
- Strong brand reputation in the ART market.
- Proprietary technologies and intellectual property.
Ueber HTLZF
Hamilton Thorne Ltd., headquartered in Beverly, Massachusetts, develops, manufactures, and markets precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company's history is rooted in providing cutting-edge solutions for the ART field, evolving from precision laser systems to a comprehensive suite of products and services. Hamilton Thorne's offerings include precision laser systems, imaging systems, and other equipment and consumables under the Hamilton Thorne brand. Additionally, the company provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration, and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand. The company also manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics under the Gynemed brand. Furthermore, Hamilton Thorne offers bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand. The company sells its products and services through a direct sales force in the United States, Germany, France, and the United Kingdom, as well as through distributors to approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries.
Was das Unternehmen tut
- Develops precision laser systems for assisted reproductive technologies (ART).
- Manufactures imaging systems for cell biology research.
- Offers consumables for ART procedures.
- Provides software solutions for managing ART processes.
- Distributes equipment and disposables for reproductive medicine.
- Offers test laboratory and endotoxin testing services.
- Supplies fresh and cryopreserved mouse embryos.
- Provides technician training and proficiency testing services.
Geschaeftsmodell
- Direct sales of precision instruments, consumables, and software to fertility clinics and research institutions.
- Distribution through partners in approximately 75 countries.
- Service contracts for maintenance and support of equipment.
- Revenue from testing services and training programs.
Branchenkontext
Hamilton Thorne Ltd. operates within the assisted reproductive technology (ART) industry, a sector experiencing steady growth due to rising infertility rates, advancements in reproductive technologies, and increasing awareness of ART procedures. The global ART market is projected to reach billions of dollars by 2026, driven by factors such as delayed pregnancies, lifestyle changes, and medical conditions affecting fertility. The competitive landscape includes companies offering similar ART equipment, consumables, and services. Hamilton Thorne differentiates itself through its comprehensive product portfolio, global reach, and focus on innovation and customer service.
Wichtige Kunden
- Fertility clinics
- Hospitals
- Pharmaceutical companies
- Biotechnology companies
- Educational institutions
- Commercial and academic research establishments
Finanzdaten
Chart & Info
Hamilton Thorne Ltd. (HTLZF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer HTLZF verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer HTLZF.
Kursziele
Wall-Street-Kurszielanalyse fuer HTLZF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von HTLZF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Ekaterina Torchilin MBA,
Chief Executive Officer
Ekaterina Torchilin holds an MBA and has extensive experience in the healthcare industry, particularly in the field of assisted reproductive technologies. Her background includes leadership roles in various medical device and biotechnology companies, where she focused on strategic planning, product development, and market expansion. She brings a wealth of knowledge in commercializing innovative healthcare solutions and driving business growth.
Erfolgsbilanz: Under Ekaterina Torchilin's leadership, Hamilton Thorne Ltd. has focused on expanding its global presence and enhancing its product portfolio. Key achievements include strategic acquisitions to broaden the company's offerings and investments in research and development to drive innovation. She has also overseen efforts to improve operational efficiency and strengthen customer relationships.
HTLZF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Hamilton Thorne Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and there may be concerns about their financial viability or regulatory compliance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential for delisting or trading suspension.
- Verify the company's registration and regulatory filings.
- Review the company's financials, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Established history in the ART market.
- Global distribution network and customer base.
- Proprietary technologies and intellectual property.
- Experienced management team.
- Positive customer reviews and testimonials.
Haeufige Fragen zu HTLZF
What are the key factors to evaluate for HTLZF?
Hamilton Thorne Ltd. (HTLZF) currently holds an AI score of 53/100, indicating moderate score. Key strength: Comprehensive product portfolio for ART and cell biology.. Primary risk to monitor: Potential: Competition from established and emerging ART equipment and service providers.. This is not financial advice.
How frequently does HTLZF data refresh on this page?
HTLZF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HTLZF's recent stock price performance?
Recent price movement in Hamilton Thorne Ltd. (HTLZF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive product portfolio for ART and cell biology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HTLZF overvalued or undervalued right now?
Determining whether Hamilton Thorne Ltd. (HTLZF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HTLZF?
Before investing in Hamilton Thorne Ltd. (HTLZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HTLZF to a portfolio?
Potential reasons to consider Hamilton Thorne Ltd. (HTLZF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Comprehensive product portfolio for ART and cell biology.. Additionally: Global distribution network and direct sales force.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of HTLZF?
Yes, most major brokerages offer fractional shares of Hamilton Thorne Ltd. (HTLZF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HTLZF's earnings and financial reports?
Hamilton Thorne Ltd. (HTLZF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for HTLZF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- OTC data may be limited or unaudited.
- AI analysis pending for additional insights.